Skip to main content
Future Journal of Pharmaceutical Sciences

Table 2 Carrageenan induced acute inflammatory model in WS rats

From: Screening assessment of trimethoxy flavonoid and - (-)-epigallocatechin-3-gallate against formalin-induced arthritis in Swiss albino rats and binding properties on NF-κB-MMP9 proteins

Group

Treatment and dose

Paw volume (mL)

(0 h)

Paw volume (mL)

(6 h)

Inhibition (%)

I

Carrageenan

0.8

1.9 ± 0.02##

 

II

EGCG-LD

0.9

1.1 ± 0.02**

43

III

TMF-LD

1

1.25 ± 0.01**

35

IV

EGCG-HD

0.9

1.06 ± 0.01*

45

V

TMF-HD

0.85

0.87 ± 0.02*

55

VI

Indomethacin

0.8

0.85 ± 0.03**

56

  1. Values are mean S.E.M.; n = 6; Treatment group *p < 0.001; **p < 0.01 vs. carrageenan control; ##p < 0.05 vs. saline control. The paw volume was measured in every 1 h and upto 6 h. The paw volume for normal control paw was 0.95 ± 0.02
Back to article page